US Patent Issued to Ipsen Biopharm, Galderma Holding on April 14 for "Treatment of moderate to very severe glabellar lines and lateral canthal lines" (Swedish Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,599,549, issued on April 14, was assigned to Ipsen Biopharm Ltd. (Wrexham, Great Britain) and Galderma Holding SA (Zug, Switzerland).

"Treatment of moderate to very severe glabellar lines and lateral canthal lines" was invented by Andrew Pickett (Uppsala, Sweden), Birgitta Almegard (Uppsala, Sweden), Charlotta Gauffin (Vange, Sweden), Aleksandra Karin (Uppsala, Sweden), Anna Nilsson (Uppsala, Sweden) and Axel Emilson (Uppsala, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods of treatment of moderate to severe and very severe glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions. Also ...